
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Ruben Mesa, MD, Director of UT Health San Antonio MD Anderson Cancer Center, presents data from the 2021 European Hematology Association Virtual Congress from the SIMPLIFY-1 and SIMPLIFY-2 trials of patients with myelofibrosis who were treated with momelotinib.
Ruben Mesa, MD, discusses data from the following presentation:

